Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TOP1 | P11387 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 7/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10050486 | 0.93 | RAB9A (0.51) | RAB9AMAPTSMN1; SMN2TOP1BACE1 | |
| SCHEMBL14528653 | 0.88 | RAB9A (0.46) | RAB9AMAPTSMN1; SMN2TOP1BACE1 | |
| SCHEMBL10050504 | 0.88 | RAB9A (0.52) | RAB9AMAPTSMN1; SMN2TOP1BACE1 | |
| SCHEMBL10075064 | 0.87 | RAB9A (0.49) | RAB9AMAPTSMN1; SMN2BACE1HPGD | |
| SCHEMBL10074756 | 0.83 | RAB9A (0.50) | RAB9AMAPTSMN1; SMN2BACE1HPGD | |
| SCHEMBL10050498 | 0.81 | RAB9A (0.43) | RAB9AMAPTSMN1; SMN2BACE1HPGD | |
| SCHEMBL8908471 | 0.78 | RAB9A (0.52) | RAB9AMAPTSMN1; SMN2BACE1HPGD | |
| SCHEMBL10050497 | 0.78 | RAB9A (0.44) | RAB9AMAPTSMN1; SMN2BACE1HPGD | |
| SCHEMBL9230080 | 0.73 | TOP1 (0.60) | RAB9AMAPTTOP1NPC1 | |
| SCHEMBL2549051 | 0.73 | TOP1 (0.60) | RAB9AMAPTTOP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8092661-B2 | Electropolymerisable monomers, soluble in an aqueous solution and comprising a metalloporphyrin | BIOMERIEUX (FR) | 2012-01-10 | — | — | US | disclosed |
| US-8092661-B2 | Electropolymerisable monomers, soluble in an aqueous solution and comprising a metalloporphyrin | BIOMERIEUX (FR) | 2012-01-10 | — | — | US | disclosed |
| US-20090314660-A1 | Novel Electropolymerisable Monomers, Soluble in an Aqueous Solution and Comprising a Metalloporphyrin | BIOMERIEUX (FR) | 2009-12-24 | — | — | US | disclosed |
| US-20090314660-A1 | Novel Electropolymerisable Monomers, Soluble in an Aqueous Solution and Comprising a Metalloporphyrin | BIOMERIEUX (FR) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090314660-A1 | Novel Electropolymerisable Monomers, Soluble in an Aqueous Solution and Comprising a Metalloporphyrin | EPS15, PPOX, ACR | RAB9A 4754/4885MAPT 2894/4885SMN1; SMN2 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.